Estrogen Receptor Positive Breast Cancer Recruiting Phase 3 Trials for Pertuzumab (DB06366)

Also known as: Oestrogen receptor positive breast cancer

IndicationStatusPhase
DBCOND0049177 (Estrogen Receptor Positive Breast Cancer)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02947685Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerTreatment